OTC Releases Bravo 2.7 Diagnostic Software Update for Encore
OTC, a Bosch Automotive Service Solutions brand, has released an Encore diagnostics software update that expands vehicle information and coverage to 642 new systems and 2,314 new vehicle-ECU combinations.
The company says Encore’s Bravo 2.7 release improves capabilities for technicians, adding more tests and vehicle coverage while making the tool faster and more responsive.
Highlights of the software release include TPMS updates and improvements to tests for diagnosing various issues with Ford, Chrysler and Toyota vehicles. In total, the release increases coverage for 642 new systems and 2,314 new vehicle-ECU combinations. With the update, technicians can expand their testing and diagnostic capabilities within the shop as they work to fix customer vehicles.
Additional Encore software enhancements include:
- ABS functional tests for many 2000-2005 vehicles;
- tire pressure reset tests for many 2000-2005 vehicles;
- throttle position tests for many 2005-2009 vehicles;
- tire type/pressure selection tests for many 2011 vehicles;
- EVAP (evaporative) tests for numerous Ford and Toyota models; and
- DEF (diesel exhaust fluid) tests for 2013-2015 Chrysler vehicles.
Encore software updates include global OBD II coverage in Spanish. For more information on the latest Encore software update release visit the company's website.
Diagnostics for Life
All Encore owners with an active diagnostics subscription can download the latest update now and take advantage of the new vehicle coverage and tests. Technicians must maintain an active, continuous diagnostics subscription to keep their lifetime warranty active, receive future coverage updates and benefit from the Diagnostics for Life program. Maximizing convenience, technicians can renew directly on Encore to save time.
The Diagnostics for Life program applies to existing and future purchasers of the Encore. To qualify for Diagnostics for Life, technicians must only maintain an active, uninterrupted diagnostics subscription with OTC.